Furthermore, Calidi Biotherapeutics has disclosed its intention to conduct a public offering of its common stock, with the potential inclusion of pre-funded warrants. The details of the offering, including size and terms, remain undetermined and will be dictated by market conditions. Ladenburg Thalmann & Co. Inc. has been named as the exclusive placement agent for this offering.